1. Home
  2. WIW vs ASMB Comparison

WIW vs ASMB Comparison

Compare WIW & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Inflation-Linked Opportunities & Income Fund

WIW

Western Asset Inflation-Linked Opportunities & Income Fund

HOLD

Current Price

$8.68

Market Cap

540.9M

Sector

Finance

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$36.12

Market Cap

553.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIW
ASMB
Founded
2004
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
540.9M
553.6M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
WIW
ASMB
Price
$8.68
$36.12
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$43.40
AVG Volume (30 Days)
229.9K
131.0K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
11.14%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$37,191,000.00
Revenue This Year
N/A
$42.01
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
31.30
52 Week Low
$8.01
$7.75
52 Week High
$9.37
$39.71

Technical Indicators

Market Signals
Indicator
WIW
ASMB
Relative Strength Index (RSI) 39.10 57.82
Support Level $8.67 $35.05
Resistance Level $8.73 $38.82
Average True Range (ATR) 0.07 1.91
MACD -0.00 -0.32
Stochastic Oscillator 0.00 42.70

Price Performance

Historical Comparison
WIW
ASMB

About WIW Western Asset Inflation-Linked Opportunities & Income Fund

Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: